Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study.

Langmead L, Dawson C, Hawkins C, Banna N, Loo S, Rampton DS.

Aliment Pharmacol Ther. 2002 Feb;16(2):197-205.

3.

Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis.

Millar AD, Rampton DS, Chander CL, Claxson AW, Blades S, Coumbe A, Panetta J, Morris CJ, Blake DR.

Gut. 1996 Sep;39(3):407-15.

4.

Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease.

Carty E, Macey M, McCartney SA, Rampton DS.

Aliment Pharmacol Ther. 2000 Jun;14(6):807-17.

5.

Depleted mucosal antioxidant defences in inflammatory bowel disease.

Buffinton GD, Doe WF.

Free Radic Biol Med. 1995 Dec;19(6):911-8.

PMID:
8582668
6.

Use of herbal preparations in the treatment of oxidant-mediated inflammatory disorders.

Kaplan M, Mutlu EA, Benson M, Fields JZ, Banan A, Keshavarzian A.

Complement Ther Med. 2007 Sep;15(3):207-16. Epub 2006 Aug 21. Review.

PMID:
17709066
7.

Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro.

Langmead L, Makins RJ, Rampton DS.

Aliment Pharmacol Ther. 2004 Mar 1;19(5):521-7.

PMID:
14987320
9.

Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease.

Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, Verspaget HW.

J Pathol. 2003 Sep;201(1):17-27.

PMID:
12950013
10.
11.

Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease.

Carty E, MacEy M, Rampton DS.

Aliment Pharmacol Ther. 2000 Sep;14(9):1169-79.

12.

Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study.

Gisbert JP, Luna M, González-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Maté J.

Gastroenterol Hepatol. 2008 Oct;31(8):477-84.

PMID:
18928745
13.

Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis.

Swidsinski A, Loening-Baucke V, Bengmark S, Lochs H, Dörffel Y.

Inflamm Bowel Dis. 2007 Jan;13(1):51-6.

PMID:
17206639
14.

5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.

Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S.

Inflamm Bowel Dis. 2006 Apr;12(4):251-7.

PMID:
16633046
15.

Diarrhea as a side effect of mesalamine treatment for inflammatory bowel disease.

Goldstein F, DiMarino AJ Jr.

J Clin Gastroenterol. 2000 Jul;31(1):60-2.

PMID:
10914779
16.

Anti-inflammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content.

Sandoval M, Okuhama NN, Zhang XJ, Condezo LA, Lao J, Angeles' FM, Musah RA, Bobrowski P, Miller MJ.

Phytomedicine. 2002 May;9(4):325-37.

PMID:
12120814
17.

Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species.

Miyachi Y, Yoshioka A, Imamura S, Niwa Y.

Gut. 1987 Feb;28(2):190-5.

18.

5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.

Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT.

Inflamm Bowel Dis. 2007 Apr;13(4):367-71.

PMID:
17206695
19.
20.

5-ASA and lycopene decrease the oxidative stress and inflammation induced by iron in rats with colitis.

Reifen R, Nissenkorn A, Matas Z, Bujanover Y.

J Gastroenterol. 2004 Jun;39(6):514-9.

PMID:
15235867

Supplemental Content

Support Center